IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Core Insights - IO Biotech is preparing to present an update on the development and launch of its investigational cancer vaccine, Cylembio™, at the 45th Annual Cowen Health Care Conference scheduled for March 3-5, 2025 [1][2] - The company is conducting pivotal Phase 3 and Phase 2 clinical trials for Cylembio™, which targets advanced melanoma and other solid tumors in combination with Merck's KEYTRUDA [3][4][5] Company Overview - IO Biotech is a clinical-stage biopharmaceutical company focused on developing immune-modulatory, off-the-shelf therapeutic cancer vaccines using its T-win platform [5] - The lead candidate, Cylembio™, is designed to activate T cells against tumor cells and immune-suppressive cells in the tumor microenvironment [3][5] - The company has received Breakthrough Therapy Designation from the US FDA for Cylembio™ in combination with KEYTRUDA for advanced melanoma treatment [5] Clinical Trials - Ongoing clinical trials include a pivotal Phase 3 trial (IOB-013/KN-D18) and two Phase 2 basket trials (IOB-022/KN-D38 and IOB-032/PN-E40) [3][4] - Enrollment for all three trials has been completed, with the trials sponsored by IO Biotech in collaboration with Merck [4]